Changing the future of Oncology.
About Sutro Biopharma
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — antibody conjugates, bispecific antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.
Precision protein engineering generates superior molecules
3 product candidates in the clinic as a result of research innovations
Premier collaborations with Bristol-Myers Squibb, Merck, EMD Serono and SutroVax
Great people making excellence happen, every day!
Our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify optimal molecules designed for safety and potency.
SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia
Foster City, CA, March 26, 2020 – SutroVax, a biopharmaceutical company dedicated to the delivery of superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the closing of a $110...
Sutro Biopharma Reports Full Year 2019 Financial Results and Recent Business Highlights and Developments
STRO-002 Data from an Ongoing Phase 1 Clinical Trial in Ovarian and Endometrial Cancers Late-Breaking Abstract was accepted by AACR; Sutro plans to announce updated data in second quarter 2020 STRO-001 Phase 1 Clinical Trial and Dose Escalation Ongoing in Multiple...
Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck
SOUTH SAN FRANCISCO, Calif., March. 12, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...